Compare HIHO & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | OGEN |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.6M |
| IPO Year | 2002 | 2010 |
| Metric | HIHO | OGEN |
|---|---|---|
| Price | $0.92 | $0.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.2K | ★ 409.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | ★ 82.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.11 |
| 52 Week High | $2.21 | $9.16 |
| Indicator | HIHO | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 56.45 |
| Support Level | $0.89 | $0.82 |
| Resistance Level | $1.21 | $0.90 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 31.54 | 56.49 |
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.